key: cord-0939963-8n2jxaem
authors: Prattes, Juergen; Wauters, Joost; Giacobbe, Daniele Roberto; Lagrou, Katrien; Hoenigl, Martin
title: Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry
date: 2021-07-16
journal: Intensive Care Med
DOI: 10.1007/s00134-021-06471-6
sha: 806f9abf26c351475fb3199e88e91f78dede1918
doc_id: 939963
cord_uid: 8n2jxaem

nan

Graz (EC #32-296 ex 19/20) and the other participating centers.

A total of 592 cases were entered (98.5% from Europe; for demographics see Supplementary Table 1 ) of whom 11 (1.9%) had proven CAPA, 80 (13.5%) probable CAPA and 18 (3%) possible CAPA. Table 1 displays diagnostic characteristics of those with CAPA. Median BALF-GM optical density index (ODI) in 83 CAPA patients was 2.74 (IQR 1.70-5.78). BALF-GM ODI > 1.0 was also reported in 4/170 (2.4%) patients without CAPA. BALF culture growing Aspergillus was detected exclusively among CAPA patients (0/184 non-CAPA patients). Serum GM was positive (> 0.5 ODI) in 1/192 patients without CAPA (0.5%). Antifungal treatment details are depicted in Table 1 . Among those receiving systemic antifungal treatment, 52% were alive at ICU discharge.

During a median observation time of 32 days, 261 ICU deaths were observed. This corresponded to an − 30, − 60 and − 90 day ICU mortality of 36% (95% CI 33-40), 46% (95% CI 42-51) and 49% (95% CI 44-53). By applying a Fine-Gray competing risk model the 109 diagnosed CAPA cases (i.e., possible, probable or proven) on ICU corresponded to an − 1, − 15-and − 90 day ICU CAPA rate of 1% (95% CI 1-3), 16% (95% CI 13-20) and 20% (95% CI 16-32) ( Supplementary Fig. 1 ).

Overall CAPA prevalence in our cohort was 15.4% and, therefore, within the range that has been previously reported in the literature [5] , although prevalence varied widely between centers. Several factors such as awareness, diagnostic algorithms, local epidemiology and socioeconomic factors may explain these differences. Our results confirm that diagnosis of CAPA remains a challenge with limited sensitivity of serum GM (19%) for CAPA and the need for a lower respiratory sample or tracheal/bronchial/lung biopsy to confirm diagnosis. Early diagnosis is considered a cornerstone in successful CAPA management, as ICU mortality rate is high in CAPA patients (52% versus 39% in non-CAPA COVID-19 patients on ICU; p = 0.027). Voriconazole and isavuconazole were most frequently used for antifungal monotherapy, following current treatment recommendations for CAPA [4] . Even though > 90% of CAPA patients received antifungal treatment, there was also one CAPA case not receiving antifungal therapy among the survivors, indicating that not all patients who are diagnosed with CAPA based on consensus definitions may in fact have invasive fungal disease.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s00134-021-06471-6. 

BALF bronchoalveolar lavage fluid, CAPA COVID-19-associated pulmonary aspergillosis, ODI optical density index, PCR polymerase chain reaction *CAPA cases: Leuven, Belgium (n = 9); Genoa, Italy (n = 5); Graz, Austria (2 centers, n = 13); Cologne, Germany (n = 19); Manchester, UK (n = 2); Antwerp, Belgium (n = 12); Bruges, Belgium (n = 2); Roeselare, Belgium (n = 1); Munich, Germany (n = 13); Madrid, Spain (n = 12); Nuernberg, Germany (n = 5); Stuttgart, Germany (n = 2); Bordeaux, France (n = 5); Karachi, Pakistan (n = 4); Ann Arbor, USA (n = 3); Besancon, France (n = 1); Modena, Italy (n = 1) 

COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment

Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

European Confederation of Medical M, International Society for Human Animal M, Asia Fungal Working G, Group ILIW, Group IPAMW, European Society for Clinical M, Infectious Diseases Fungal Infection Study G, Patients ESGfIiCI, Interregional Association of Clinical M, Antimicrobial C, Medical Mycology Society of N, Medical Mycology Society of China Medicine Education A, Infectious Diseases Working Party of the German Society for H, Medical O, Association of Medical M, Infectious Disease C, (2020) Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

Invasive fungal disease complicating COVID-19: when it rains it pours

Acknowledgements section at the end of the article.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.